Data Insights

Venetoclax by AbbVie for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Human Immunodeficiency Virus (HIV) Infections (AIDS)

Data Insights

Venetoclax by AbbVie for Myelodysplastic Syndrome: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase III for Myelodysplastic Syndrome. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Myelodysplastic Syndrome

Data Insights

Venetoclax by AbbVie for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)....

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

Data Insights

Venetoclax by AbbVie for Natural Killer Cell Lymphomas: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase I for Natural Killer Cell Lymphomas. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Natural Killer Cell Lymphomas

Data Insights

Venetoclax by AbbVie for Myeloproliferative Disorders: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Myeloproliferative Disorders. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Myeloproliferative Disorders

Data Insights

Venetoclax by AbbVie for Solid Tumor: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Solid Tumor

Data Insights

Venetoclax by AbbVie for Amyloidosis: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Amyloidosis. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Amyloidosis

Data Insights

Venetoclax by AbbVie for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

Venetoclax by AbbVie for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase I for Marginal Zone B-cell Lymphoma. According to GlobalData,...

Data Insights

Venetoclax by AbbVie for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to GlobalData,...

Data Insights

Venetoclax by AbbVie for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData,...

Data Insights

Venetoclax by AbbVie for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData,...

Data Insights

Venetoclax by AbbVie for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase I for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid...

Data Insights

Venetoclax by AbbVie for Mantle Cell Lymphoma: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase III for Mantle Cell Lymphoma. According to GlobalData, Phase...

Data Insights

Venetoclax by AbbVie for Natural Killer Cell Lymphomas: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase I for Natural Killer Cell Lymphomas. According to GlobalData,...

Data Insights

Venetoclax by AbbVie for Myeloproliferative Disorders: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Myeloproliferative Disorders. According to GlobalData, Phase II...

Data Insights

Venetoclax by AbbVie for Solid Tumor: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Data Insights

Venetoclax by AbbVie for Amyloidosis: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Amyloidosis. According to GlobalData, Phase II drugs...

Data Insights

Venetoclax by AbbVie for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...

Data Insights

Venetoclax by AbbVie for Follicular Lymphoma: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II...